Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01810575 · ClinicalTrials.gov registry record · Phase 2
Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction
A Phase 2 study, sponsored by Warner Chilcott.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01810575 is a Phase 2 study that was terminated before completion, run by Warner Chilcott. The registered enrollment target is 16 participants.
The verdict
NCT01810575, a Phase 2 study, was terminated before completion, sponsored by Warner Chilcott.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety \& efficacy of a single dose of alprostadil cream with 2 concentrations of WC3036 compared to vehicle alone in men with erectile dysfunction.
Interventions
- DRUG WC3036-11F/Alprostadil in Vehicle 2.5%
- DRUG WC3036-12F/Alprostadil in Vehicle 0.5%
- DRUG WC3036-13P/Vehicle Only 0.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01810575
The ClinicalTrials.gov registry entry for NCT01810575 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which WC3036-11F/Alprostadil in Vehicle 2.5% is the first listed.
NCT01810575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01810575 about?
NCT01810575 is a clinical study titled "Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction". The purpose of this study is to assess the safety \& efficacy of a single dose of alprostadil cream with 2 concentrations of WC3036 compared to vehicle alone in men with erectile dysfunction.
What is the current status of trial NCT01810575?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2013-02. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01810575?
The interventions under investigation include: WC3036-11F/Alprostadil in Vehicle 2.5% (DRUG), WC3036-12F/Alprostadil in Vehicle 0.5% (DRUG), WC3036-13P/Vehicle Only 0.5% (DRUG).
Who is sponsoring clinical trial NCT01810575?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.